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Rhabdomyosarcoma is a malignant soft-tissue sarcoma that
accounts for 6–7% of all cancers in children (Enzinger and Weiss,
1995). Drugs commonly used to treat this disease include the vinca
alkaloids, anthracyclines, etoposide and cyclophosphamide. Initial
treatment is often successful but relapse due to drug resistance
remains a major obstacle to survival. In some, but not all, studies
the expression of P-glycoprotein (P-gp, encoded by the mdr-1
gene) in clinical samples has been associated with adverse prog-
nosis (Chan et al, 1990; Kuttesch et al, 1996). Our more recent in
vitro studies have shown that relatively low levels of P-gp and the
multidrug resistance-related protein (MRP) may contribute to
resistance (Cocker et al, 2000). 
The MDM2 protein is often overexpressed in sarcomas and has
been shown to be overexpressed in some rhabdomyosarcoma cell
lines in vitro (Keleti et al, 1996; Cocker et al, 2000; Taylor et al,
2000) and occasionally (approximately 10% of cases) in patient
tumour specimens (Meddeb et al, 1996; Taylor et al, 2000). The
MDM2 protein binds and inactivates the tumour suppressor protein
P53 and in turn p53 is a transcriptional trans-activator of MDM2.
Mutant p53 has also recently been shown to stabilise MDM2 (Peng
et al, 2001). It also interacts with proteins such as p19-ARF and Rb
to control cellular growth (Ashcroft and Vousden, 1999). As well as
a link being shown between p53 and mdr-1 (Chin et al, 1992;
Thottassery et al, 1997), a direct link may exist between the expres-
sion of MDM2 and the expression of mdr-1. In one example, trans-
fection of a glioblastoma line with the mdm2 gene resulted in
increased expression of both the mdr-1 gene and functionally
active P-gp (Kondo et al, 1996). However, the absence of data for
appropriate empty vector controls in this study does not exclude
the possibility that the increased expression of mdr-1 resulted from
the transfection process itself. In addition, it is unclear whether the
increase was mediated by interaction of MDM2 with P53, which
may affect expression of mdr-1 (Li et al, 1997). Alternatively,
there may be direct activation of transcription by MDM2
(Leveillard and Wasylyk, 1997). There are also clinical studies
which have linked expression of MDM2 with resistance to
doxorubicin in acute lymphoblastic leukaemia (Zhou et al, 1997)
and breast carcinoma (Suzuki et al, 1998) but conversely, expres-
sion of mdm2 mRNA has been correlated with increased duration
of survival in ovarian cancer (Tanner et al, 1997). 
This study employed stable transfection of mdm2 into human
rhabdomyosarcoma (RMS) cell lines to address whether (a)
MDM2 regulates the expression of MDR genes in rhabdomyosar-
coma and (b) whether this confers multidrug resistance. We have
used 4 well characterised human rhabdomyosarcoma cell lines
with lines selected on the basis of previous experiments deter-
mining constitutive expression of P53, MDM2 and P-gp (Cocker
et al, 2000). Of the 4 lines only one, SCMC, has wild-type P53
function. The remaining lines, Rh30, RMS and RD all have point
mutations in the p53 gene although some evidence of P53 function
(up-regulation of P21 following irradiation) has been demon-
strated in RMS (Cocker et al, 2000). 
MATERIALS AND METHODS 
Cell lines 
This study uses 4 rhabdomyosarcoma cell lines, as described
previously (Cocker et al, 2000). Rh30 (mutant p53) was a gift
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from Dr PJ Houghton (St Judes Children’s Research Hospital).
SCMC (p53 wild-type) was a gift from T Sawada (Kyoto
Prefectual University of Medicine, Japan). RMS and RD (both
mutant p53) were obtained from the American Type Culture
Collection (Manassas, VA, USA). The human ovarian carcinoma
cell lines CH1 and its multidrug resistant variant CH1DoxR were
used as negative and positive controls for mdr-1 and P-gp expres-
sion (Sharp et al, 1994). The human non-small-cell lung carci-
noma cell line CORL23 and its multidrug resistant variant
CORL23/R were used as negative and positive controls for mrp1
expression (Barrand et al, 1994). 
All cell lines were maintained in RPMI 1640 medium (Sigma,
Poole, Dorset, UK) supplemented with 10% fetal bovine serum
(Life Technologies, Scotland, UK) and 2 mM L-glutamine
(Sigma). Cells were grown as attached monolayers and were incu-
bated at 37˚C in a humidified atmosphere with 5% CO2. All cell
lines were routinely screened for Mycoplasma by PCR assay
(Stratagene, Cambridge, UK). 
Drugs and chemicals 
Vincristine (David Bull Laboratories) and Etoposide (Bristol
Myers Squibb Pharmaceuticals) stock solutions were obtained as
pharmacy preparations at concentrations of 1.083 mM and 34 mM
respectively. Doxorubicin (Sigma) was dissolved in water to give a
stock solution of 1 mM. Cisplatin (Johnson Matthey Technology
Centre, Reading, UK) was dissolved in 0.9% saline to give a stock
solution of 1 mM. PSC833 (Novartis, Basel, Switzerland) was
dissolved in absolute ethanol to give a 1 mM stock. All these drugs
were stored at –20˚C with the exception of vincristine which was
stored at 4˚C. Immediately before use the drugs were diluted with
RPMI 1640 medium prepared as for cell culture, with the excep-
tion of vincristine which was diluted in RPMI medium without
any supplements. 
MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenylterazolium
bromide) (Sigma) was dissolved in PBS to produce a stock solu-
tion of 5 mg ml–1 which was stored at 4˚C. Puromycin (Sigma) was
dissolved in water to give a stock solution of 250 µ g ml–1 and
stored at –20˚C. 
Transfection 
The plasmid vector pEFIRES-P (also known as F373) contains the
puromycin resistance gene (pac) and the gene of interest within a
single transcription cassette designed to produce a bicistronic
message (Hobbs et al, 1998). A cDNA containing the human
mdm2 coding sequence (originally obtained from Dr B Vogelstein)
was cloned into the multiple cloning site of F373, resulting in the
vector F407. Cell lines were transfected with F373 or F407 by
DOTAP lipofection (Roche Diagnostics Ltd, Lewes, E Sussex,
UK) using a 6 hour incubation with 5 µ g of vector DNA
complexed with 30 µ l DOTAP. The cells were then incubated in
growth medium for 48 hours to recover and then exposed to
puromycin at 0.3–0.5 µ g ml–1, a concentration pre-determined to
kill all non-transfected cells. Surviving colonies were selected
after 3 weeks and analysed for MDM2 expression by immunoblot-
ting. Puromycin selection was maintained until one week before
experiments. 
Immunoblotting 
Immunoblotting was carried out as described previously (Cocker
et al, 2000). The antibody IF-2 (Oncogene, Cambridge, MA, USA)
was used to detect MDM2, C219 (Centocor, USA) was used to
detect PgP from membrane preparations, DO-1 (Santa Cruz) was
used to detect p53 and B-1-5-2 (Sigma) was used to detect 
α -tubulin to ensure equal loading of wells in all experiments. 
Growth inhibition assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay (Mosmann, 1983), using 4 days continuous expo-
sure, was used to measure growth inhibition, as previously
described (Cocker et al, 2000). The effects of the modulator
PSC833 on growth inhibition were also tested by this method.
PSC833 was added immediately before addition of the cytotoxic
agent at a concentration which kills less than 10% of cells (2 µ M). 
Clonogenic assay 
A clonogenic assay was used to measure cell survival. Briefly,
cells were added to 6-well plates at concentrations of between
1 × 103 and 5 × 103 cells per well. The cytotoxic agents doxoru-
bicin, vincristine, etoposide and cisplatin were added 24 h later.
The cells were then incubated for a further 5 days after which the
drug was removed. The experiment was terminated after a further
4–8 days, dependent on the cell line used. Surviving colonies were
stained using methylene blue (0.5% methylene blue in 50%
methanol) (Sigma) for 15 minutes, air dried and counted. The
number of surviving colonies of greater than approximately 50
cells was expressed as a percentage of the number of colonies
surviving in the absence of drug. Plating efficiency was between
4–10%. 
Real-time PCR 
Relative expression of mdr-1 and mrp1 genes was measured using
Taqman Real-time PCR (PE Applied Biosystems, Foster City, CA,
USA), using the ABI Prism 7700 sequence detection system. 1 µ g
of total RNA was reverse transcribed in a 20 µ l volume using
Superscript reverse transcriptase (Life Technologies, Paisley, UK)
and random hexanucleotides (Amersham Pharmacia Biotech UK
Ltd, Bucks, UK), according to the manufacturer’s instructions.
Real-time PCR for mdr-1 was performed in a final volume of
25 µ l containing 1X TaqMan® Universal PCR Master Mix (PE
Biosystems), 900 nM forward primer (5′ -AAAAGTGAAAA-
AGATAAGAAGGAAAAGAAA-3′ ), 900 nM reverse primer 
(5′ -CACCATATACAACTTGTCAAGCCAA-3′ ) and 150 nM
FAM/TAMRA dual-labelled oligonucleotide probe (5′ -FAM-
TTGAATAGCGAAACATTGAAAATACACTGACAGTTG-
TAMRA-3′ ). Real-time PCR for mrp1 was performed in a final
volume of 25 µ l containing 1X TaqMan® Universal PCR Master
Mix, 300 nM forward primer (5′ -AGATGACACCTCTCAA-
CAAAACCA-3′ ), 300 nM reverse primer (5′ -AGGTCTGC-
CCAGCAGACG-3′ ) and 50 nM FAM/TAMRA dual-labelled
oligonucleotide probe (5′ -FAM- AACTGCCTTGGGATTTTTG-
CTGTGGA-TAMRA-3′ ). Both primer and probe sets amplified
across an exon/exon boundary, to prevent amplification of1748 HA Cocker et al
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genomic DNA. 0.1 µ l of cDNA was used in each reaction. To
measure the total amount of sample RNA present, levels of 18S
rRNA were quantitated in each reaction using TaqMan®
Ribosomal RNA Control Reagents with a VIC/TAMRA oligo-
nucleotide probe (PE Biosystems). Relative expression of mdr-1
and mrp1 was calculated from standard curves generated from cell
lines CH1DoxR and CORL23/R respectively. 
Cloning of mrp1 cDNA 
PCR amplification of cDNA from Rh30 cells was used to produce
a 140 bp fragment of the mrp1 gene. The primers were as previ-
ously published (Bordow et al, 1994). The amplified fragment was
ligated into the pCR-Script™ Cam cloning vector (Stratagene)
according to the manufacturer’s instructions. The clones obtained
were sequenced to check insert size, sequence and orientation. The
plasmid was then digested using PvuII to generate a 588 bp frag-
ment to use as a template. 
RNAse protection 
α -32P-labelled RNA transcripts complementary to actin, mdr-1 and
mrp1 cDNA sequences were transcribed using a T7 polymerase
MAXIscript kit (Ambion, Austin, TX, USA). The templates used
were pTRI-β -actin-125-Human (Ambion), pTRI-MDR-1 (Ambion)
and the MRP template generated as described above. The resulting
probes were purified on a denaturing 5% polyacrylamide gel.
Hybridisation of probes and sample RNA was carried out using the
RPA III kit (Ambion). The resulting protected fragments and
unprotected controls were separated by electrophoresis using the
QuickPoint nucleic acid separation system (Novex, San Diego,
CA, USA). Bands were visualised using a phosphorimager
(Molecular Dynamics, Sevenoaks, UK). 
Statistical analysis 
Where appropriate, statistical significance was tested using a 2-
tailed Student’s t-test. 
RESULTS 
The cell lines were transfected with the F407 construct which
includes the full-length human mdm2 gene. This resulted in
increased levels of the 90 kDa MDM2 protein in all 4 cell lines
when compared to the parental (w.t.) line or the F373 empty vector
control (Figure 1). Various clones were selected and one (of very
similar phase contrast morphology and doubling time) chosen for
initial sensitivity determinations. Transfection with the empty vector
control F373 occasionally also appeared to result in a small increase
in MDM2 expression in 2 cell lines, SCMC and RD (as shown in
Figure 1), whereas there was no change in Rh30 and RMS. The
doubling times of the selected transfected cell lines were not signifi-
cantly different from the parent cell lines (data not shown). 
A growth inhibition assay was used to measure the sensitivity of
the cell lines (parent line and a representative F373 empty vector
and F407 mdm2 clone of each) to the commonly used agents
cisplatin, doxorubicin, etoposide and vincristine (Figure 2A–D,
respectively). Transfection of the cell line RD (p53 mutant) with
the F407 vector resulted in significantly decreased sensitivity to all
4 agents. The decrease was particularly marked with vincristine
(61.1-fold), doxorubicin (6.4-fold) and etoposide (4.8-fold). The
F407-transfected SCMC line (p53 wild type) also showed signifi-
cantly decreased sensitivity to vincristine (5.8-fold), doxorubicin
(5.4-fold) and etoposide (2.4-fold), but not to cisplatin. In contrast,
no significant changes in sensitivity were seen with any agent in
RMS, which constitutively overexpresses MDM2. In Rh30 there
was a significant decrease in sensitivity to doxorubicin, but this
was lower (1.5-fold) than that observed in SCMC and RD. The
sensitivity of the transfected empty vector control lines did not
differ markedly from that of the respective parental cell lines for
any of the 4 agents. 
In order to add confirmation to these observations, clonogenic
survival assays were also carried out. These were less reproducible
due to generally low plating efficiency but confirmed the results of
the growth inhibition assay. Representative results for vincristine
are shown (Figure 2E, F). The mdm2 transfected RD cell line is
significantly resistant to vincristine (67-fold) when compared with
the parent line whereas there is no change in RMS. 
As we observed an increased resistance to the known MDR
substrate doxorubicin in 3 out of 4 mdm2-transfected lines, we
evaluated whether the increased resistance was attributable to
increased mdr-1 or mrp1 gene expression. Real-time PCR was
used to measure expression of mdr-1 and mrp1 genes in the cell
line panel (Figure 3A, B). Expression of mdr-1 was undetectable
in the cell lines Rh30 and RMS and their transfected variants. The
line SCMC has moderate expression of mdr-1 (as noted pre-
viously) (Cocker et al, 2000), which increases significantly
following transfection with F407. Transfection of the line RD with
F407 but not F373 results in a highly significant increase in mdr-1
expression. In all the cell lines, mrp1 expression is similar and
remains unchanged following transfection. These results were
confirmed using RNAse protection assay (Figure 3C). Both
methods demonstrated increased expression of the mdr-1 gene in
MDM2
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Figure 1 Typical immunoblot for MDM2 and α -tubulin in a panel of rhabdomyosarcoma cell lines and their empty vector (F373) and mdm2 gene (F407)
transfected variants. Data are shown for one representative clone for each of the F373 empty vector and F407 mdm2 gene transfects Expression of mdr-1 following mdm2 transfection 1749
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Figure 2 Sensitivity of a panel of parent human rhabdomyosarcoma cell lines or transfected with empty vector (F373) or the mdm2 gene (F407) to: 
(A) cisplatin, (B) doxorubicin, (C) etoposide and (D) vincristine. IC50 values given are the mean + standard deviation for one representative clone as shown
in Figure 1, from 3 independent experiments each containing quadruplicate measurements. Values represent fold-change in sensitivity. *indicates significantly
greater than F373 transfect (P < 0.05) in a 2-tailed Student’s t-test. The clonogenic assay was used to measure survival of cell lines (E) RMS and (F) RD
following treatment with vincristine. Data points are the mean ± standard deviation from 3 independent experiments.   w.t.,   empty vector (F373) transfect, 
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the mdm2-transfected variants of SCMC and RD, thus correlating
with the sensitivity data. As reported previously (Cocker et al,
2000) PgP levels were too low to be detectable using immunoblot-
ting and the C-219 antibody. Although levels were also low in the
F407 transfects, detectable PgP expression was apparent in
the mdm2-transfected variants of SCMC and RD (data not shown). 
The P-gp modulator PSC833 (Naito and Tsuruo, 1997) was used
to confirm that P-gp contributes to resistance in the F407- trans-
Figure 3 Expression of MDR-related genes mdr-1 (A) and mrp1 (B) in human rhabdomyosarcoma cell lines transfected with empty vector (F373) or the mdm2
gene (F407). Values shown are the mean + standard deviation from 3 independent experiments. nd = not detectable. *indicates significantly greater than F373
transfect (P < 0.001 in a 2-tailed Student’s t-test). (C) Expression of MDR-related genes by RNAse protection assay. Modulation of sensitivity using PSC833
in (D) SCMC and (E) RD wild-type cell lines (open bars) and mdm2 gene (F407) transfected variants (closed bars). PSC833 was added to the MTT assay
immediately before addition of the cytotoxic agent at a concentration which kills less than 10% of cells (2 µ M). Values given are the mean + standard deviation
of 3 independent experiments each containing quadruplicate measurements. Sensitisation ratio (SR) = IC50 in the absence of modulator/ IC50 in the presence of
modulator. 
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fected SCMC and RD cell lines (Figure 3D, E). A sensitisation
ratio greater than 1 indicates that modulation of sensitivity is
taking place. PSC833 has no effect on sensitivity to cisplatin in either
of the cell lines. In contrast, modulation of sensitivity to vincristine,
doxorubicin and etoposide is greater in the F407-transfected lines
than in their untransfected counterparts. This is particularly
marked for vincristine where modulation is increased from 14-fold
to 31-fold in SCMC F407 and from 1.6-fold to 156-fold in 
RD F407. 
These results suggest that overexpression of the MDM2 protein
may, in some cell lines, lead to an increase in expression of the
mdr-1 gene and P-gp, thereby conferring resistance to multiple
agents. There is a possibility however, that these observations may
be specific to our chosen clones. To test this we screened several
transfected clones of Rh30 and RD for MDM2 expression and
mdr-1 expression (Figure 4). mrp1 expression was also measured
but was not changed in any of the clones (data not shown). In the
cell line Rh30, transfection with F373 or F407 did not result in
detectable expression of the mdr-1 gene even though clear
increases in MDM2 expression were observed (Figure 4A). In
contrast, transfection of RD with F373 led to a small increase in
expression of the MDM2 protein, concomitant with a small
increase in the mdr-1 gene, in 2 out of 3 clones. This was to a
much lesser extent than following transfection with the F407
construct when both MDM2 and mdr-1 expression were signifi-
cantly increased in all 5 clones (Figure 4B). 
DISCUSSION 
One previous study has suggested a possible role for MDM2 in the
regulation of mdr1 expression (Kondo et al, 1996). However, it is
unclear whether this single observation is applicable to tumour
types such as rhabdomyosarcoma where elevated MDM2 is occa-
sionally observed or is dependent on aspects of the cell phenotype
such as expression of mdr1, P53 and MDM2 itself. In order to
further investigate this, we transfected the mdm2 gene into a panel
of 4 human rhabdomyosarcoma cell lines and tested their sensi-
tivity to drugs commonly used to treat this disease, including
MDR substrates. 
Our results indicate that stable overexpression of MDM2
protein was achieved in all 4 cell lines and this conferred a range in
response to the drugs cisplatin, doxorubicin, etoposide and
vincristine. In 2 cell lines, SCMC and RD, marked resistance was
observed to the P-glycoprotein substrates doxorubicin, etoposide
and especially vincristine. In contrast, no effect on drug sensitivity
was observed in the RMS cell line (that already overexpresses
MDM2 protein) and only low-level resistance (1.5-fold) to one
drug (doxorubicin) was observed in Rh30 cells. The profile of
resistance in SCMC and RD suggests an MDR mechanism as the
largest changes are seen with the P-gp substrates but not with
cisplatin. In a few cases, transfection with the empty F373 vector
also caused a small increase in expression of MDM2. This
increase was much smaller than with the F407 mdm2 construct and
could reflect either clonal selection or a stress response to transfec-
tion or puromycin selection. 
To aid confirmation of the mechanism of resistance, expression
of the MDR genes was analysed using both real-time PCR and
RNAse protection assays. Both methods demonstrated increased
expression of the mdr-1 gene in the mdm2-transfected variants of
SCMC and RD, thus correlating with the drug sensitivity data. No
significant changes were seen with the empty vector controls or in
mrp1 expression. The highly sensitive real-time PCR assay shows
that the cell lines SCMC and RD both show low constitutive
expression of mdr-1 whereas Rh30 and RMS do not. This suggests
that the activation of mdr-1 expression by MDM2 may only occur
when basal expression of mdr-1 is already present. We then used
the P-gp modulator PSC833 to confirm that the increased expres-
sion of mdr-1 leads to an increase in functional P-gp. In the mdm2-
transfected variants of SCMC and RD, resistance to vincristine,
doxorubicin and etoposide could be modulated using PSC833
whereas sensitivity to cisplatin remained unchanged. 
To confirm that our observations were not clone-dependent we
screened a series of transfected clones for MDM2, mdr-1 and mrp1
expression. No changes in mrp1 expression were seen, indicating
that MDM2 has no influence on this gene. In the cell line Rh30
transfection with F373 or F407 did not result in detectable expres-
sion of the mdr1 gene even though clear increases in MDM2
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Figure 4 Expression of the mdr-1 gene by real-time PCR and MDM2 by
immunoblotting in clones of (A) Rh30 and (B) RD. w.t. = wild type, F373 =
empty vector transfected, F407 = mdm2 gene transfected. Values are the
mean + standard deviation of at least 5 independent measurements.
*indicates significantly greater than wild type (P < 0.001 in a 2-tailed
Student’s t-test) 1752 HA Cocker et al
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protein were detected with the F407 transfects. In contrast, trans-
fection of the F407 construct into RD cells resulted in overexpres-
sion of MDM2 protein and a significant increase in the mdr1 gene
in all 5 clones. These observations support the hypothesis that
increases in mdr-1 expression are only seen when basal expression
is present, as in RD and SCMC. Reports suggest that MDM2 may
function as a transcription factor (Leveillard and Wasylyk, 1997). If
MDM2 is able to influence transcription of the mdr-1 gene this may
only occur when the promoter region is already active. 
Of interest was that, of the 2 cell lines where high levels of
mdm2 caused an increase in drug resistance, SCMC possesses
wild-type p53 while RD is mutant. We also evaluated the selected
clones for constitutive p53 expression using an antibody (DO-1)
which detects both wild-type and mutant forms. The 3 p53 mutant
lines (RD, RMS and Rh30) all showed high constitutive levels of
p53 in empty vector F373 control and F407 mdm2 transfects (data
not shown). In contrast, the F407 mdm2 transfects of SCMC
showed higher constitutive p53 expression than either the vector
controls or parent line. It would be of interest to evaluate relation-
ships between mdm2 and induction of mdr-1 in a p53 null rhab-
domyosarcoma cell line such as Rh4 (Taylor et al, 2000). The
changes in drug sensitivity observed in the mutant p53 RD cell line
may relate to the recent observation of mutant p53 stabilising
MDM2 (Peng et al, 2001). 
In conclusion, we have confirmed that overexpression of MDM2
may increase the expression of the mdr-1 gene. This may be depen-
dent on the presence of mdr-1 transcription before transfection
takes place. MDM2 overexpression often occurs during the devel-
opment of malignancy, especially in soft tissue sarcomas. These
data are in agreement with one previous report where mdm2 was
transfected into a human glioblastoma cell line and selected using
G418 (Kondo et al, 1996). However, in contrast to our studies, no
sensitivity data are reported for empty vector control clones. A
recent study found amplification of the mdm2 gene in 2/20 cases of
rhabdomyosarcoma (Taylor et al, 2000). In our own studies of
mdm2 gene expression in 28 rhabdomyosarcoma clinical samples,
4 (14%) expressed high levels as measured by real-time PCR
(unpublished observations). It is therefore conceivable that in some
tumours, mdr-1 expression may be increased before any treatment
takes place and this may influence the management of disease.
These data also suggest that inhibition of MDM2 function (eg. by
small molecules or antisense oligonucleotides) may be used in
some rhabdomyosarcoma tumours to prevent resistance to MDR
substrates. Our models provide further evidence for a relationship
between MDM2 and mdr-1. However, in our initial study of 28
clinical samples we did not observe high mdr-1 expression in the 4
samples with high mdm2 expression (data not shown). A larger
study in clinical samples both at diagnosis and after chemotherapy
or at relapse is required to confirm the clinical significance. 
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